Neuronal nicotinic receptor subtypes: Defining therapeutic targets

被引:57
作者
Buccafusco, J
机构
[1] Med Coll Georgia, Alzheimers Res Ctr, Augusta, GA 30912 USA
[2] Augusta Vet Adm Med Ctr, Augusta, GA USA
[3] ASPET, Div Syst & Integrated Pharmacol, Bethesda, MD 20814 USA
关键词
D O I
10.1124/mi.4.5.8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Humans have appreciated the beneficial properties of the tobacco plant for thousands of years. These effects include alertness, reduced anxiety, muscle relaxation, and analgesia. Yet it has been less than two decades since the central actions of nicotine have been examined in earnest for potential therapeutic applications. In fact, the cholinergic systems, in comparison to other neurotransmitter systems of the body, have been relatively poorly exploited in terms of therapeutic agents, and the muscarinic cholinergic systems have been relegated mainly to the treatment of gastaroinstestinal disorders and glaucoma; for the nicotinic system,antagonists are used to induce muscle paralysis during certain surgical procedures. For both families of cholinergic receptors, widespread exploitation in terms of therapeutics has been limited by significant side effect profiles associated with available cholinergic drugs.
引用
收藏
页码:285 / 295
页数:11
相关论文
共 61 条
[1]   Choline is a selective agonist of α7 nicotnic acetylcholine receptors in the rat brain neurons [J].
Alkondon, M ;
Pereira, EFR ;
Cortes, WS ;
Maelicke, A ;
Albuquerque, EX .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1997, 9 (12) :2734-2742
[2]  
ARNERIC SP, NICOTINE PSYCHIAT, P3
[3]   Ventral hippocampal α4β2 nicotinic receptors and chronic nicotine effects on memory [J].
Bancroft, A ;
Levin, ED .
NEUROPHARMACOLOGY, 2000, 39 (13) :2770-2778
[4]  
Bencherif M, 1998, J PHARMACOL EXP THER, V284, P886
[5]  
BENOWITZ NL, 1986, ANNU REV MED, V37, P21
[6]  
BENOWITZ NL, 1988, PHARM NICOTINE, P3
[7]  
Bontempi B, 2001, J PHARMACOL EXP THER, V299, P297
[8]   Gain of function mutation of the α7 nicotinic receptor:: distinct pharmacology of the human α7V274T variant [J].
Briggs, CA ;
McKenna, DG ;
Monteggia, LM ;
Touma, E ;
Roch, JM ;
Arneric, SP ;
Gopalakrishnan, M ;
Sullivan, JP .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 366 (2-3) :301-308
[9]   Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists [J].
Briggs, CA ;
McKenna, DG .
NEUROPHARMACOLOGY, 1998, 37 (09) :1095-1102
[10]   Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo [J].
Briggs, CA ;
Anderson, DJ ;
Brioni, JD ;
Buccafusco, JJ ;
Buckley, MJ ;
Campbell, JE ;
Decker, MW ;
DonnellyRoberts, D ;
Elliott, RL ;
Gopalakrishnan, M ;
Holladay, MW ;
Hui, YH ;
Jackson, WJ ;
Kim, DJB ;
Marsh, KC ;
ONeill, A ;
Prendergast, MA ;
Ryther, KB ;
Sullivan, JP ;
Arneric, SP .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 57 (1-2) :231-241